, Tracking Stock Market Picks
Enter Symbol:
Rating: REGN
Hold $525

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) downgraded to Hold with price target $525 by Canaccord Genuity

Wednesday,  Jan 27, 2016  9:25 AM ET by Kristen Bailey

Canaccord Genuity downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Hold with price
target $525. Canaccord Genuity rated Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Buy with price target $700 on 08/05/2015, when the price was $592.80.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy